drugset
drugset / Trial / NCT04871646

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314

NCT04871646 ↗

Phase 3 Unknown 586 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Double-blind, Multi-center, Multi-regional, Randomized controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with COVID-19

Timeline

Start
2021-06-30
Primary completion
2022-03
Completion
2022-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nafamostat Small molecule — Intravenous

Indications

pneumonia